8 articles
Stanford researchers developed a nasal spray vaccine that, in mice, broadly protects against various respiratory viruses, bacteria, and allergens for months by boosting innate immunity. Human trials are next.
Stanford researchers develop a universal nasal spray vaccine, tested in animals, that primes lung immune cells to broadly fight viruses, bacteria, and allergens, marking a radical new approach to immunization.
A mucosal vaccine clears C. difficile from the gut, preventing infection and recurrence, unlike traditional systemic vaccines.
Bacteria's Clover anti-phage system uses enzymes to dynamically control a defense enzyme, balancing viral restriction with avoiding cellular toxicity.
The brain's dural sinuses are active, not passive, veins. They dynamically regulate blood flow, fluid exchange, and immune cell surveillance, which is crucial for antiviral defense.
A nasal spray vaccine tested in mice activates the innate immune system, providing months of broad protection against various respiratory viruses, bacteria, and allergens. If effective in humans, it could become a universal seasonal vaccine.
A universal nasal spray vaccine tested in animals could protect against many viruses, bacteria, and allergies by putting lung immune cells on high alert, marking a radical new approach. Human trials are needed.
A universal nasal spray vaccine tested in animals could protect against many viruses, bacteria, and allergies by putting lung immune cells on high alert. Experts call it exciting but early-stage research.